Abstract
Raloxifene, previously known as keoxifene, is a benzothiophene-selective estrogen receptor modulator used as an alternative to conventional hormone replacement therapy in postmenopausal women. Raloxifene provides some of the benefits of estrogen, without the stimulatory activity on breast tissue. Raloxifene has been shown to prevent osteoporosis in postmenopausal women (1) and to decrease the risk of vertebral fracture (2). Raloxifene also has favorable effects on biochemical markers of cardiovascular disease by decreasing low-density lipoprotein cholesterol and lipoprotein (a) and by increasing high-density lipoprotein 2 cholesterol (3). Raloxifene has also been found not to stimulate growth of cultured human breast cancer cells (4). In addition, it acts similarly to tamoxifen, inhibiting the effects of estrogen in rat mammary carcinoma models (4–6).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
